Clinical Trials Logo

SMARCA4 Gene Mutation clinical trials

View clinical trials related to SMARCA4 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT05639751 Recruiting - Clinical trials for Advanced Solid Tumor

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Start date: May 2, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of PRT3789 monotherapy and in combination with docetaxel, describe any dose limiting toxicities (DLTs), define the dosing schedule, and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) to be used in subsequent development of PRT3789.

NCT ID: NCT01238250 Recruiting - Clinical trials for STXBP1 Encephalopathy With Epilepsy

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

Start date: October 2010
Phase:
Study type: Observational

Simons Searchlight is an observational, online, international research program for families with rare genetic variants that cause neurodevelopmental disorders and may be associated with autism. Simons Searchlight collects medical, behavioral, learning, and developmental information from people who have these rare genetic changes. The goal of this study is to improve the clinical care and treatment for these people. Simons Searchlight partners with families to collect data and distribute it to qualified researchers.